darolutamide
General
Pronunciation:
dar-oh-loo-ta-mide
Trade Name(s)
- Nubeqa
Ther. Class.
Pharm. Class.
androgen receptor inhibitors
Indications
Non-metastatic castration resistant prostate cancer.
Action
Acts as an androgen receptor inhibitor, preventing the binding of androgen; decreases proliferation and induces cell death of prostate cancer cells.
Therapeutic Effect(s):
Decreased growth and spread of prostate cancer.
Pharmacokinetics
Absorption: 30% absorbed following oral administration; absorption increased with food.
Distribution: Extensively distributed to tissues.
Protein Binding: Darolutamide– 92%; Keto-darolutamide– 99.8%.
Metabolism and Excretion: Primarily metabolized in the liver by the CYP3A4 isoenzyme as well as by UGT1A1 and UGT1A9 to an active metabolite (keto-darolutamide). Primarily excreted in urine (63%, 7% as unchanged drug) and 32% excreted in feces (30% as unchanged drug).
Half-life: 20 hr.
TIME/ACTION PROFILE (plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 4 hr | unknown |
Contraindication/Precautions
Contraindicated in:
- End-stage renal disease (CCr <15 mL/min)
- Severe hepatic impairment;
- OB: Pregnancy (may cause fetal harm).
Use Cautiously in:
- Severe renal impairment (CCr 15–29 mL/min) (↓ dose)
- Moderate hepatic impairment (↓ dose)
- Rep: Men with female partners of reproductive potential
- Pedi: Safety and effectiveness not established in children.
Adverse Reactions/Side Effects
CV: HF, ischemic heart disease
Derm: rash
GI: hyperbilirubinemia, ↑ liver enzymes
Hemat: NEUTROPENIA
Neuro: fatigue
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Interactions
Drug-Drug
- Concurrent use with a combined P-glycoprotein and strong or moderate CYP3A4 inducer, including rifampin , may ↓ levels and effectiveness; avoid concurrent use.
- Concurrent use with a combined P-glycoprotein and strong CYP3A4 inhibitor, including itraconazole , may ↑ levels and the risk of toxicity; avoid concurrent use.
- May ↑ levels of BCRP substrates, including rosuvastatin ; avoid concurrent use.
Route/Dosage
Patients should also be taking a gonadotropin-releasing hormone (GnRH) analog or should have undergone a bilateral orchiectomy.
PO (Adults): 600 mg (2 × 300–mg tablets) twice daily.
Renal Impairment
PO (Adults): Severe renal impairment (CCr 15–29 mL/min)– 300 mg twice daily.
Hepatic Impairment
PO (Adults): Moderate hepatic impairment (Child–Pugh Class B)– 300 mg twice daily.
Availability
Film-coated tablets: 300 mg
Assessment
- Monitor for pain in extremities during therapy.
Lab Test Considerations:
May cause neutropenia, and increased AST and bilirubin.
Potential Diagnoses
- Deficient knowledge, related to medication regimen (Patient/Family/Teaching)
Implementation
- Patients should also be taking a gonadotropin-releasing hormone (GnRH) analog concurrently of have had a bilateral orchiectomy.
- PO Administer twice daily with food. Swallow tablets whole; do not crush, break, or chew.
Patient/Family Teaching
- Instruct patient to take darolutamide as directed. Take missed doses as soon as remembered, but do not take two doses together to make up for a missed dose. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
- Inform patient of importance of continuing therapy with gonadotropin-releasing hormone during therapy with darolutamide.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Rep: Advise male patients with female partners of reproductive potential to use effective contraception and avoid breastfeeding during and for 1 wk after last dose. Inform patient that darolutamide may impair fertility.
Evaluation/Desired Outcomes
Decreased growth and spread of prostate cancer.
To view other topics, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.